Literature DB >> 29898905

Tuberculosis elimination: where are we now?

Alberto Matteelli1, Adrian Rendon2, Simon Tiberi3, Seif Al-Abri4, Constantia Voniatis5, Anna Cristina C Carvalho6, Rosella Centis7, Lia D'Ambrosio7,8, Dina Visca9, Antonio Spanevello9,10, Giovanni Battista Migliori7.   

Abstract

Tuberculosis (TB) still represents a major public health issue in spite of the significant impact of the efforts made by the World Health Organization (WHO) and partners to improve its control. In 2014 WHO launched a new global strategy (End TB) with a vision of a world free of TB, and a 2035 goal of TB elimination (defined as less than one incident case per million). The aim of this article is to summarise the theoretical bases of the End TB Strategy and to analyse progresses and persistent obstacles on the way to TB elimination.The evolution of the WHO recommended strategies of TB control (Directly Observed Therapy, Short Course (DOTS), Stop TB and End TB) are described and the concept of TB elimination is discussed. Furthermore, the eight core activities recently proposed by WHO as the milestones to achieve TB elimination are discussed in detail. Finally, the recently published experiences of Cyprus and Oman on their way towards TB elimination are described, together with the regional experience of Latin America.New prevention, diagnostic and treatment tools are also necessary to increase the speed of the present TB incidence decline.
Copyright ©ERS 2018.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29898905     DOI: 10.1183/16000617.0035-2018

Source DB:  PubMed          Journal:  Eur Respir Rev        ISSN: 0905-9180


  21 in total

Review 1.  Rifamycin antibiotics and the mechanisms of their failure.

Authors:  Rebekah A Adams; Gabrielle Leon; Natalia M Miller; Saira P Reyes; Chantal H Thantrong; Alina M Thokkadam; Annabel S Lemma; Darshan M Sivaloganathan; Xuanqing Wan; Mark P Brynildsen
Journal:  J Antibiot (Tokyo)       Date:  2021-08-16       Impact factor: 2.649

2.  Impact of the COVID-19 Pandemic on the Diagnosis of Tuberculosis in Brazil: Is the WHO End TB Strategy at Risk?

Authors:  Mariana do Rosário Souza; Wandklebson Silva da Paz; Vinícius Barbosa Dos Santos Sales; Gleidson Felipe Hilario de Jesus; Débora Dos Santos Tavares; Shirley V M Almeida Lima; Álvaro Francisco Lopes Sousa; Enaldo Vieira de Melo; Rodrigo Feliciano do Carmo; Carlos Dornels Freire de Souza; Márcio Bezerra-Santos
Journal:  Front Pharmacol       Date:  2022-06-29       Impact factor: 5.988

3.  Modeling the impact of COVID-19 on future tuberculosis burden.

Authors:  Mario Tovar; Alberto Aleta; Joaquín Sanz; Yamir Moreno
Journal:  Commun Med (Lond)       Date:  2022-06-29

4.  Compliance with Tuberculosis Screening in Irregular Immigrants.

Authors:  Francesca Bonvicini; Silvia Cilloni; Rossano Fornaciari; Carmen Casoni; Cristina Marchesi; Marina Greci; Lucia Monici; Fausto Nicolini; Marco Vinceti
Journal:  Int J Environ Res Public Health       Date:  2018-12-23       Impact factor: 3.390

Review 5.  Tuberculosis Genetic Epidemiology: A Latin American Perspective.

Authors:  Marc Woodman; Ilsa L Haeusler; Louis Grandjean
Journal:  Genes (Basel)       Date:  2019-01-16       Impact factor: 4.096

6.  Incidence Rates for Tuberculosis Among HIV Infected Patients in Northern Tanzania.

Authors:  Edson W Mollel; Werner Maokola; Jim Todd; Sia E Msuya; Michael J Mahande
Journal:  Front Public Health       Date:  2019-10-24

7.  Tuberculosis preventive treatment: the next chapter of tuberculosis elimination in India.

Authors:  Patrick K Moonan; Sreenivas A Nair; Reshu Agarwal; Vineet K Chadha; Puneet K Dewan; Umesh D Gupta; Christine S Ho; Timothy H Holtz; Ajay M Kumar; Nishant Kumar; Prahlad Kumar; Susan A Maloney; Sundari R Mase; John E Oeltmann; C N Paramasivan; Malik M Parmar; Kiran K Rade; Ranjani Ramachandran; Raghuram Rao; Virendra S Salhorta; Rohit Sarin; Sanjay Sarin; Kuldeep S Sachdeva; Sriram Selvaraju; Rupak Singla; Diya Surie; Jamhoih Tonsing; Srikanth P Tripathy; Sunil D Khaparde
Journal:  BMJ Glob Health       Date:  2018-10-08

8.  Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial.

Authors:  Tsegahun Manyazewal; Yimtubezinash Woldeamanuel; David P Holland; Abebaw Fekadu; Henry M Blumberg; Vincent C Marconi
Journal:  Trials       Date:  2020-05-05       Impact factor: 2.279

9.  Latent Tuberculosis Infection Treatment Completion while Shifting Prescription from Isoniazid-Only to Rifampicin-Containing Regimens: A Two-Decade Experience in Milan, Italy.

Authors:  Simone Villa; Maurizio Ferrarese; Giovanni Sotgiu; Paola Francesca Castellotti; Laura Saderi; Cecilia Grecchi; Matteo Saporiti; Mario Raviglione; Luigi Ruffo Codecasa
Journal:  J Clin Med       Date:  2019-12-31       Impact factor: 4.241

10.  Multidrug- and Extensively Drug-Resistant Mycobacterium tuberculosis Beijing Clades, Ukraine, 2015.

Authors:  Matthias Merker; Elena Nikolaevskaya; Thomas A Kohl; Barbara Molina-Moya; Olha Pavlovska; Patrik Brännberg; Andrii Dudnyk; Valentyna Stokich; Ivan Barilar; Iryna Marynova; Tetiana Filipova; Cristina Prat; Anders Sjöstedt; Jose Dominguez; Olena Rzhepishevska; Stefan Niemann
Journal:  Emerg Infect Dis       Date:  2020-03       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.